{
  "name": "First Tracks Biotherapeutics, Inc.",
  "legal_name": "First Tracks Biotherapeutics, Inc.",
  "ticker": "TRAX",
  "tickers": [
    "TRAX"
  ],
  "cik": "0002091349",
  "page_url": "https://steadybase.io/company/first-tracks-biotherapeutics-inc/",
  "markdown_url": "https://steadybase.io/company/first-tracks-biotherapeutics-inc.md",
  "json_url": "https://steadybase.io/company/first-tracks-biotherapeutics-inc.json",
  "as_of": "2026-11-21",
  "last_filed": "2026-11-03",
  "industry": {
    "sic": "2834",
    "description": "Pharmaceutical Preparations"
  },
  "headquarters": {
    "city": "San Diego",
    "state": "CA",
    "country": "US"
  },
  "exchanges": [
    "Nasdaq"
  ],
  "fiscal_year_end": "December 31",
  "filer_category": "Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company",
  "state_of_incorporation": "DE",
  "website": "firsttracksbio.com",
  "investor_relations_url": "https://ir.firsttracksbio.com/news-events/news-releases",
  "linkedin_company_url": "https://www.linkedin.com/company/firsttracksbiotherapeutics",
  "summary": {
    "text": "First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator.com or follow us on LinkedIn .",
    "section": "Press release \"About\" paragraph",
    "period_end": "2026-10-15",
    "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000119312526422929/trax-ex99_1.htm"
  },
  "key_facts": [
    {
      "key": "shares_outstanding",
      "label": "Shares outstanding",
      "value": 42017901,
      "unit": "shares",
      "period_end": "2026-10-29",
      "form": "10-Q",
      "filed": "2026-11-03",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000119312526445430/0001193125-26-445430-index.html",
      "text": "Shares outstanding: 42,017,901 as of Oct 29, 2026 (10-Q filed Nov 3, 2026)."
    }
  ],
  "metrics": {},
  "next_earnings": {
    "date": "2027-02-02",
    "confidence": "low",
    "webcast_url": null
  },
  "people": [
    {
      "name": "Daniel Faga",
      "title": "President and chief executive officer",
      "role": "officer",
      "linkedin_url": null,
      "form": "8-K",
      "filed": "2026-11-03",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000119312526445405/trax-ex99_1.htm"
    },
    {
      "name": "Ajim Tamboli",
      "title": "Chief Financial Officer",
      "role": "officer",
      "linkedin_url": "https://linkedin.com/in/ajim-tamboli",
      "form": "4",
      "filed": "2026-05-14",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000185568426000008/0001855684-26-000008-index.htm"
    },
    {
      "name": "Benjamin Stone",
      "title": "Chief Business Officer",
      "role": "officer",
      "linkedin_url": "https://linkedin.com/in/benjamin-stone-a2ab4612",
      "form": "4",
      "filed": "2026-08-18",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000212878626000006/0002128786-26-000006-index.htm"
    },
    {
      "name": "Paul F. Lizzul",
      "title": "Chief Medical Officer",
      "role": "officer",
      "linkedin_url": null,
      "form": "4",
      "filed": "2026-08-18",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000171146226000014/0001711462-26-000014-index.htm"
    }
  ],
  "events_8k": [
    {
      "filed": "2026-11-03",
      "items": [
        {
          "item": "2.02",
          "label": "Results of operations and financial condition (earnings release)",
          "signal": "earnings"
        },
        {
          "item": "9.01",
          "label": "Financial statements and exhibits",
          "signal": "exhibits"
        }
      ],
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000119312526445405/trax-20261103.htm"
    },
    {
      "filed": "2026-10-20",
      "items": [
        {
          "item": "1.01",
          "label": "Entry into a material definitive agreement",
          "signal": "deal"
        },
        {
          "item": "9.01",
          "label": "Financial statements and exhibits",
          "signal": "exhibits"
        }
      ],
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000119312526426666/trax-20261019.htm"
    },
    {
      "filed": "2026-10-15",
      "items": [
        {
          "item": "1.01",
          "label": "Entry into a material definitive agreement",
          "signal": "deal"
        },
        {
          "item": "3.02",
          "label": "Unregistered sales of equity securities",
          "signal": "financing"
        },
        {
          "item": "7.01",
          "label": "Regulation FD disclosure",
          "signal": "disclosure"
        },
        {
          "item": "9.01",
          "label": "Financial statements and exhibits",
          "signal": "exhibits"
        }
      ],
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000119312526422929/trax-20261015.htm"
    },
    {
      "filed": "2026-10-13",
      "items": [
        {
          "item": "7.01",
          "label": "Regulation FD disclosure",
          "signal": "disclosure"
        },
        {
          "item": "8.01",
          "label": "Other events",
          "signal": "other"
        },
        {
          "item": "9.01",
          "label": "Financial statements and exhibits",
          "signal": "exhibits"
        }
      ],
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000119312526419761/trax-20261012.htm"
    },
    {
      "filed": "2026-08-12",
      "items": [
        {
          "item": "2.02",
          "label": "Results of operations and financial condition (earnings release)",
          "signal": "earnings"
        },
        {
          "item": "9.01",
          "label": "Financial statements and exhibits",
          "signal": "exhibits"
        }
      ],
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000119312526346908/trax-20260812.htm"
    },
    {
      "filed": "2026-06-22",
      "items": [
        {
          "item": "1.01",
          "label": "Entry into a material definitive agreement",
          "signal": "deal"
        }
      ],
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000119312526277504/trax-20260615.htm"
    },
    {
      "filed": "2026-05-14",
      "items": [
        {
          "item": "2.02",
          "label": "Results of operations and financial condition (earnings release)",
          "signal": "earnings"
        },
        {
          "item": "9.01",
          "label": "Financial statements and exhibits",
          "signal": "exhibits"
        }
      ],
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000119312526224124/trax-20260514.htm"
    },
    {
      "filed": "2026-04-20",
      "items": [
        {
          "item": "1.01",
          "label": "Entry into a material definitive agreement",
          "signal": "deal"
        },
        {
          "item": "2.01",
          "label": "Completion of acquisition or disposition of assets",
          "signal": "m_and_a"
        },
        {
          "item": "3.02",
          "label": "Unregistered sales of equity securities",
          "signal": "financing"
        },
        {
          "item": "3.03",
          "label": "Material modification to rights of security holders",
          "signal": "governance"
        },
        {
          "item": "5.01",
          "label": "Changes in control of registrant",
          "signal": "m_and_a"
        },
        {
          "item": "5.02",
          "label": "Departure or appointment of directors or officers; compensation",
          "signal": "leadership_change"
        },
        {
          "item": "5.03",
          "label": "Amendments to articles or bylaws; change in fiscal year",
          "signal": "governance"
        },
        {
          "item": "8.01",
          "label": "Other events",
          "signal": "other"
        },
        {
          "item": "9.01",
          "label": "Financial statements and exhibits",
          "signal": "exhibits"
        }
      ],
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/d78703d8k.htm"
    },
    {
      "filed": "2026-04-03",
      "items": [
        {
          "item": "7.01",
          "label": "Regulation FD disclosure",
          "signal": "disclosure"
        },
        {
          "item": "9.01",
          "label": "Financial statements and exhibits",
          "signal": "exhibits"
        }
      ],
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000119312526140835/d111394d8k.htm"
    }
  ],
  "insider_trades": [
    {
      "owner": "J. Anthony Ware",
      "role": "Director",
      "action": "sold",
      "code": "S",
      "shares": 39265,
      "value_usd": 1758287,
      "date": "2026-09-02",
      "filed": "2026-09-04",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000171542926000007/0001715429-26-000007-index.htm"
    }
  ],
  "quotes": [
    {
      "text": "ANB033, a subcutaneously administered CD122 antagonist designed to inhibit signaling of both IL-15 and IL-2 on immune cells, demonstrated statistically significant protection against gluten-induced intestinal damage and symptoms and was well tolerated in the Phase 1b gluten-challenge cohort. These data support our plans to progress ANB033 into late-stage development in 2027 in celiac disease as a potential treatment to prevent both acute symptoms and intestinal damage from gl",
      "speaker": "Daniel Faga",
      "title": "president and chief executive officer",
      "form": "8-K",
      "filed": "2026-11-03",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000119312526445405/trax-ex99_1.htm"
    }
  ],
  "latest_filings": [
    {
      "form": "8-K",
      "filed": "2026-11-03",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000119312526445405/trax-20261103.htm"
    },
    {
      "form": "10-Q",
      "filed": "2026-11-03",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2091349/000119312526445430/trax-20260930.htm"
    }
  ],
  "source": "SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from."
}